Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
23-26 March, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
DCAT Week
Not Confirmed
Contact SupplierDCAT Week
Industry Trade Show
Not Confirmed
23-26 March, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content
NEWS #PharmaBuzz
09 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/bora-pharmaceuticals-and-corealis-pharma-forge-strategic-alliance-to-deliver-seamless-end-to-end-oral-solid-dose-development-302635969.html
27 Oct 2025
// CONTRACTPHARMA
https://www.contractpharma.com/breaking-news/bora-pharmaceuticals-to-scale-supply-of-oncology-therapy/
25 Sep 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/bora-biologics-to-manufacture-nypozitm-at-san-diego-facility-in-partnership-with-inva-1078073
06 Aug 2025
// CONTRACTPHARMA
https://www.contractpharma.com/breaking-news/bora-pharmaceuticals-to-expand-midwest-manufacturing-site/
22 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/upsher-smith-and-parent-company-bora-pharmaceuticals-host-iowa-governor-kim-reynolds-to-discuss-us-supply-chain-and-regional-collaboration-302510746.html
27 May 2025
// ACCESSWIRE
https://www.accessnewswire.com/newsroom/en/biotechnology/bora-biologics-expands-san-diego-facility-for-2000l-scale-biologics-manufacturing-boo-1031126
Drugs in Development
Details:
The partnership aims to advance immune health in cancer care through the development of Pegfilgrastim, a protein targeting the Granulocyte colony-stimulating factor receptor.
Lead Product(s): Pegfilgrastim,Inapplicable
Therapeutic Area: Hematology Brand Name: Udenyca
Study Phase: Approved FDFProduct Type: Protein
Sponsor: Accord BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 27, 2025
Lead Product(s) : Pegfilgrastim,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Accord BioPharma
Deal Size : Undisclosed
Deal Type : Partnership
Bora Pharmaceuticals Scaling Supply of Oncology Therapy
Details : The partnership aims to advance immune health in cancer care through the development of Pegfilgrastim, a protein targeting the Granulocyte colony-stimulating factor receptor.
Product Name : Udenyca
Product Type : Protein
Upfront Cash : Undisclosed
October 27, 2025
Details:
The collaboration aims to advance the development of DotBio’s Tri-Specific Antibody DB007 for the treatment of Cancer.
Lead Product(s): DB007,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody, Unconjugated
Sponsor: DotBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2025
Lead Product(s) : DB007,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : DotBio
Deal Size : Undisclosed
Deal Type : Collaboration
Bora Biologics, DotBio Enter Strategic CMC Development Collaboration
Details : The collaboration aims to advance the development of DotBio’s Tri-Specific Antibody DB007 for the treatment of Cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
January 09, 2025
Details:
Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.
Lead Product(s): Vigabatrin,Inapplicable
Therapeutic Area: Neurology Brand Name: Vigafyde
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Pyros Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 25, 2024
Lead Product(s) : Vigabatrin,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Pyros Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Bora Expands Rare Disease Portfolio with Pyros Pharma Acquisition
Details : Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.
Product Name : Vigafyde
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 25, 2024
Details:
Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.
Lead Product(s): Amantadine Hydrochloride,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Amantadine HCl-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Upsher-Smith Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 01, 2024
Lead Product(s) : Amantadine Hydrochloride,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Upsher-Smith Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Bora Pharmaceuticals Completes Acquisition of Upsher-Smith
Details : Through the acquisition, Bora will commercialize Amantadine HCl-Generic, which is an NMDA receptor inhibitor. It is indicated for the treatment of influenza A infections and Parkinsonism.
Product Name : Amantadine HCl-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 01, 2024
Details:
Bora acquires Upsher-Smith’s product portfolio, including Amantadine hydrochloride for treating influenza A virus infections.
Lead Product(s): Amantadine Hydrochloride,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Amantadine HCl-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Upsher-Smith Laboratories
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 18, 2024
Lead Product(s) : Amantadine Hydrochloride,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Upsher-Smith Laboratories
Deal Size : $210.0 million
Deal Type : Acquisition
CDMO Bora Pharmaceuticals Buys Generics Manufacturer Upsher-Smith for $210M
Details : Bora acquires Upsher-Smith’s product portfolio, including Amantadine hydrochloride for treating influenza A virus infections.
Product Name : Amantadine HCl-Generic
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 18, 2024
Details:
Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.
Lead Product(s): CT-G20,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Celltrion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 06, 2023
Lead Product(s) : CT-G20,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Celltrion
Deal Size : Undisclosed
Deal Type : Partnership
Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC
Details : Under the partnership, Bora will manufacture and commercialize a range of oral dosage form drugs (OSD), including CT-G20, a hypertrophic cardiomyopathy treatment candidate, across the APAC region.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 06, 2023
Details:
CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific factors.
Lead Product(s): Foslinanib,Sorafenib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: TaiRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 27, 2022
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : TaiRx
Deal Size : Undisclosed
Deal Type : Partnership
Bora Pharmaceuticals Partners with TaiRx
Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 27, 2022
Details:
Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi (L-lactic Acid), for the prevention of pregnancy, including Mexico and Nigeria.
Lead Product(s): L-Lactic Acid,Citric Acid,Potassium Bitartrate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Phexxi
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: Evofem Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 10, 2022
Lead Product(s) : L-Lactic Acid,Citric Acid,Potassium Bitartrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Evofem Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : Initially, Bora will manufacture Phexxi for nations currently considering formal regulatory approval of Phexxi (L-lactic Acid), for the prevention of pregnancy, including Mexico and Nigeria.
Product Name : Phexxi
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 10, 2022
Details:
Upon PMDA’s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory agencies around the world.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Technology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Recipient: Kyowa Pharmaceutical Industry
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 05, 2021
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Recipient : Kyowa Pharmaceutical Industry
Deal Size : Undisclosed
Deal Type : Partnership
Details : Upon PMDA’s approval, Bora will be the commercial manufacturing site for the generic product production. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory agencies around the world.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 05, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Services
Analytical
BioAnalytical Services
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Analytical Method Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drug Product Manufacturing
Spray
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Syrup
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Liquid
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Solution
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Suspension
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Biologic Drugs
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Cream / Lotion / Ointment
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Packaging
API & Drug Product Development
Formulation Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
Inspections and registrations
ABOUT THIS PAGE
Share 
